By
Publication Date: 2025-12-11 15:32:00
Nutanix finds itself at a critical juncture, with significant institutional buying activity contrasting against a recent financial forecast revision. As company executives present at the Barclays Global Technology Conference today, the market is weighing strong operational metrics against the stock’s pronounced negative reaction to its latest earnings report.
The enterprise cloud software firm reported growth for the first quarter of fiscal year 2026. Annual Recurring Revenue (ARR) climbed to $2.28 billion, an 18% year-over-year increase, while revenue reached $670.6 million, up 13%. Free Cash Flow was a robust $174.5 million, with GAAP operating income and gross margin also showing improvement.
However, management cited a delay in revenue recognition, prompting an adjustment to the full-year forecast. For FY26, revenue is now projected to be between $2.82 billion and $2.86 billion, with Free Cash Flow anticipated in the $800 million to $840 million range. The market’s response was severe: on November 26, the share price plummeted approximately 15.5%. The stock currently trades just 0.6% above its 52-week low, underscoring persistent investor anxiety.
Major Funds Boost Holdings
Recent 13F regulatory filings reveal substantial position increases by several institutional investors, indicating a portfolio rebalancing toward the enterprise software sector.
* CalPERS expanded its holding by 9.7% in the second quarter, bringing its total to 505,597 shares.
* Qube Research &…
